Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 92
Inquire Before Buying

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2017, provides an overview of the Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person's immune system (the body's natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 5 and 7 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively.

Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuromyelitis Optica (Devic's Syndrome) - Overview
Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics Development
2-BBB Medicines BV
Alexion Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Biogen Inc
Bionure Farma SL
Chugai Pharmaceutical Co Ltd
HanAll Biopharma Co Ltd
LFB SA
MedImmune LLC
Opexa Therapeutics Inc
Shire Plc
Vicore Pharma AB
Neuromyelitis Optica (Devic's Syndrome) - Drug Profiles
2B-3201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANV-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APL-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARN-6039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BN-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cladribine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNMAU-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-15107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inebilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPX-212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
satralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-623 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ublituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects
Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones
Featured News & Press Releases
Sep 16, 2016: TG Therapeutics Announces Presentation of Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Aug 31, 2016: TG Therapeutics Announces Clinical Data Presentation at the Upcoming 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Aug 26, 2016: TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab)
Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program
Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol
May 08, 2015: Initiation Of Phase I Clinical Program
Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting
Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned
Feb 25, 2015: HanAll BioPharma Receives a Grant for HL161 Auto-Immune Project from Korean Drug Development Fund
Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program
Aug 27, 2014: Clene Files Investigational New Drug Application With FDA
Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis
Apr 01, 2014: Clene Nanomedicine Requests Pre-IND Meeting With FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by 2-BBB Medicines BV, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Apellis Pharmaceuticals Inc, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Arrien Pharmaceuticals LLC, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Biogen Inc, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bionure Farma SL, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by HanAll Biopharma Co Ltd, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by LFB SA, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by MedImmune LLC, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Opexa Therapeutics Inc, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Shire Plc, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Vicore Pharma AB, H2 2017
Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects, H2 2017

List of Figures
Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Global Hormone Replacement Therapy Sales Market Report 2018
    Published: 22-Feb-2018        Price: US 4000 Onwards        Pages: 117
    In this report, the global Hormone Replacement Therapy market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Hormone Replacement Therapy for these regions, from 2013 to 2025 (forecast), covering - United States - China - Eu......
  • Global Clostridium Difficile Treatment Market Research Report 2018
    Published: 22-Feb-2018        Price: US 2900 Onwards        Pages: 116
    In this report, the global Clostridium Difficile Treatment market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Clostridium Difficile Treatment in these regions, from 2013 to 2025 (forecast), covering - North America - Eu......
  • Global Peptide Therapeutics Market Professional Survey Report 2018
    Published: 21-Feb-2018        Price: US 3500 Onwards        Pages: 100
    This report studies Peptide Therapeutics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Pfizer - Eli Lilly and Company - Bachem Holding - Amgen ......
  • Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 2000 Onwards        Pages: 113
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2018, provides an overview of the Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline landscape. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without ......
  • Liver Cirrhosis - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 2000 Onwards        Pages: 88
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H1 2018, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss o......
  • United States Liver Disease Treatment Market Report 2018
    Published: 20-Feb-2018        Price: US 3800 Onwards        Pages: 98
    In this report, the United States Liver Disease Treatment market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth ......
  • China Lupus Therapeutic Market Research Report 2018
    Published: 19-Feb-2018        Price: US 3400 Onwards        Pages: 114
    The global Lupus Therapeutic market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%. This report studies the Lupus Therapeutic development status and future trend in China, focuses on top players in China, also splits Lupus Ther......
  • Global Human Microbiome Therapeutics Market Professional Survey Report 2018
    Published: 13-Feb-2018        Price: US 3500 Onwards        Pages: 104
    This report studies Human Microbiome Therapeutics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - ENTEROME Bioscience - Rebiotix - Seres Therapeutics - ......
  • Japan Proton Therapy Market Research Report 2018
    Published: 13-Feb-2018        Price: US 1100 Onwards        Pages: 110
    The report titled “Japan Proton Therapy Market Research Report 2018” examines the market dynamics, competitive landscape and discusses major trends.  The report offers the most up-to-date industry data on the actual and potential market situation, and future outlook for proton therapy in Japan. The research includes historic data from 2012 to 2017 and forecasts until 2025. Long–term Growth Projection: Hitachi and Mitsubishi Electr......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs